华北制药股票行情怎么样

H3>Huabei Pharmaceutical (600812) Stock Market Overview

The stock market information for Huabei Pharmaceutical (600812) is as follows:

Trading Status: --

Opening Price: -

Highest Price: -

Limit Up Price: -

Turnover Rate: -

Trading Volume: -

Dynamic PE Ratio: -

Total Market Value: -

Closing Price: -

Lowest Price: -

Limit Down Price: -

Volume Ratio: -

Trading Volume: -

Price-to-Book Ratio: -

Market Capitalization: -

Summary:

Huabei Pharmaceutical (600812) recently disclosed its third quarter report for 2023. The company achieved a revenue of 2.741 billion yuan, an increase of 5.65% compared to the same period last year. The net profit attributable to the parent company was 1.4275 million yuan, a decrease of 74.33% compared to the same period last year. The non-net profit attributable to the parent company was -9.7202 million yuan, a decrease of 32.46% compared to the same period last year.

1. Revenue Performance in the Past Year

The revenue performance of Huabei Pharmaceutical (600812) in the past year is as follows: [insert table]

Explanation: [insert explanation]

2. Real-time Stock Market Trends

Huabei Pharmaceutical (600812) provides real-time stock market trends and comprehensive technical analysis, including flash intraday trends, K-line charts, average price line system, MACD, KDJ, trading volume, etc. These tools help investors make timely judgments and provide stock trading tips.

3. Capital Inflow and Outflow

On January 8, Huabei Pharmaceutical (600812) experienced selling by foreign capital, with a selling amount of 93,000 shares. On the same day, margin selling amounted to 8,640 yuan, accounting for 0.03% of the outflow amount. The data for capital inflow on January 11 shows that the main funds had a net inflow of 3.3392 million yuan.

4. Company Introduction

Huabei Pharmaceutical (600812) is a limited liability company formed in August 1992 by Huabei Pharmaceutical Factory (now Huabei Pharmaceutical Group Co., Ltd.) by injecting all of its production and operation assets and raising funds through public offering.

5. Stock Rating

Huabei Pharmaceutical (600812) has a comprehensive diagnosis rating of 3.9, surpassing 8% of other stocks. The recommended actions are sell, reduce holdings, neutral, increase holdings, and buy. In the short term, the stock market may rebound, and it is advisable to buy stocks for short-term rebound trends.

6. Holdings Changes

On January 10, Huabei Pharmaceutical was reduced by 724,800 shares by Shanghai Stock Connect. It has been continuously reduced by Shanghai Stock Connect for 5 consecutive days, with a total reduction of 1.8915 million shares. The latest holding amount is 16.2868 million shares, accounting for 0.95% of the company's total A-share capital.